HCC超声筛查中可视化评分不佳后的随访影像检查现状
可视化评分B者随访用US占58%,C者用CT/MRI占62.5%(P=.12)。
要点
- 可视化评分B者过半仍用US随访,C者约62.5%改用CT/MRI。
- B评分后MRI占55%,C评分后CT占70%,P值均无统计学意义。
- 目前无指南指导可视化不佳者的随访影像选择。
诊断标准与关键数值
- 可视化评分B者随访用US占58%,C者用CT/MRI占62.5%(P=.12)。
- 可视化评分B者随访用MRI占55%,C者用CT占70%(P=.16)。
局限性
- 单中心回顾性设计。
- 样本量及随访影像选择可能受机构习惯影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The Ultrasound Liver Imaging Reporting and Data Systems (LI-RADS) provides standardized terminology and reporting for ultrasound (US) examinations performed for hepatocellular cancer (HCC) screening. However, there are no recommendations regarding follow up imaging for visualization scores with suboptimal visualization. Therefore, the aim of this study is to examine follow up imaging practices in the setting of US studies scored as B (moderate limitations) and C (severe limitations).
METHODS: A single center retrospective analysis of studies from 2017 to 2021 with HCC US screening visualization scores of B and C was performed. Follow up imaging with US, CT, or MRI within 6 months with visualization score B or C on initial US were included.
RESULTS: Five hundred and sixty HCC US studies with suboptimal imaging were reviewed. Of those with follow up imaging, patients with a visualization score of B underwent US in more than half (58%) of the cases while those with visualization score of C underwent more CT/MRI studies (62.5%, P = .12) Patients with visualization score of B had more MRI exams performed (55%) while patients with a visualization score of C underwent more CT exams (70%, P = .16).
CONCLUSIONS: Currently, there are no guidelines instructing follow up imaging on HCC screening ultrasounds with poor visualization, and the data suggests that providers have taken a heterogeneous approach. This suggests a need for society recommendations on how to approach HCC screening ultrasounds in patients with suboptimal studies.
引用
- Bley, Mohan, Jackson, et al. Follow Up Imaging in Hepatocellular Cancer Ultrasound Screening Exams With Poor Visualization Scores. J Ultrasound Med. 2022. PMID: 36063062. doi:10.1002/jum.16093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。